Eric Wigton, MD
Ophthalmology · Swansea, ILNPI 1396926424
Payments from drug & device makers
Across 346 payments — averaging $35.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Alcon$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$416
- Bausch & Lomb Americas Inc.$340
- Aerie Pharmaceuticals, Inc.$334
- Ivantis, Inc$327
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$4,80039%
- Travel & lodging$941%
- Food & beverage$7,36060%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 142 | $7,728 |
| Alcon | 65 | $1,636 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $416 |
| Bausch & Lomb Americas Inc. | 17 | $340 |
| Aerie Pharmaceuticals, Inc. | 15 | $334 |
| Ivantis, Inc | 7 | $327 |
| Sun Pharmaceutical Industries Inc. | 16 | $247 |
| Novartis | 10 | $196 |
| Rxsight Inc | 1 | $144 |
| Shire North American Group Inc | 9 | $139 |
| Oyster Point Pharma, Inc. | 5 | $122 |
| Mallinckrodt Hospital Products Inc. | 4 | $120 |
| Thea Pharma Inc. | 5 | $103 |
| Ocular Therapeutix, Inc. | 6 | $96 |
| Tarsus Pharmaceuticals, Inc. | 4 | $95 |
| NEW World Medical,inc. | 5 | $92 |
| Dompe US, Inc. | 3 | $75 |
| Amgen | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Sight Sciences, Inc. | 2 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Harrow Eye, LLC | 1 | $13 |
| Biotissue Holdings Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$4,800
- COMBIGAN$1,800
- XEN GLAUCOMA TREATMENT SYSTEM$234
- Unity$145
- RXSIGHT CONTACT LENS$144
- RXSIGHT INJECTOR CARTRIDGE$144
- RXSIGHT INJECTOR HANDPIECE$144
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$144
- LIGHT ADJUSTABLE LENS (LAL)$144
- Hydrus$131
- Rhopressa$103
- Rocklatan$103
How this compares
$12,299 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 825 | $378,629 |
| RocklatanNetarsudil Mesylat/Latanoprost | 176 | $93,274 |
| RestasisCyclosporine | 69 | $75,692 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 430 | $75,690 |
| RhopressaNetarsudil Mesylate | 181 | $73,916 |
| CombiganBrimonidine Tartrate/Timolol | 140 | $53,206 |
| Cyclosporine | 103 | $50,919 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 208 | $48,815 |
| Prednisolone Acetate | 908 | $45,991 |
| Travoprost | 230 | $36,154 |
| Latanoprost | 3,521 | $33,466 |
| Brimonidine Tartrate | 1,161 | $33,013 |
| XiidraLifitegrast | 17 | $27,014 |
| VyzultaLatanoprostene Bunod | 42 | $23,617 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,027 | $15,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $7,728 | $511,1381,045 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $334 | $167,191357 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $340 | $50,63259 claims |
| AlconSimbrinza | $1,636 | $48,815208 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $416 | $2,89916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Swansea
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
- Kathleen MornoNorth Riverside$1.2M
- Amani FawziChicago$864K
- Navaneet Chailert BorisuthRock Island$737K
- David LubeckHomewood$709K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.